MAFLD predicts cardiovascular disease risk better than MASLD
Liver International · 2024
DOI: 10.1111/liv.15931 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Liver International, 2024. Verfasst von Ziyan Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Nutrition Surveys, Cardiovascular Diseases. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Health and Medical Research Council of Australia (NHMRC) Program Grant, Project and ideas grants, National Health and Medical Research Council.
Abstract (Originalsprache)
Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).
Methods
Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed.
Results
MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone.
Conclusions
Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia.
- Gastroenterology and Hepatology Department, Egyptian Liver Research Institute and Hospital, Mansoura, Egypt.
- Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Departement of Endemic Medicine and Hepatogastrenterology, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Gastroenterology and Hepatology Department, Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
ORCID-Profile: Gamal Shiha, Nahum Méndez-Sánchez, Mohammed Eslam
Förderung
- National Health and Medical Research Council of Australia (NHMRC) Program Grant
- Project and ideas grants
- National Health and Medical Research Council
Zitieren
APA
Pan, Z., Shiha, G., Esmat, G., Méndez-Sánchez, N., & Eslam, M. (2024). MAFLD predicts cardiovascular disease risk better than MASLD. Liver International. https://doi.org/10.1111/liv.15931
Vancouver
Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver International. 2024. doi:10.1111/liv.15931
BibTeX
@article{Pan2024,
author = {Pan, Ziyan and Shiha, Gamal and Esmat, Gamal and Méndez-Sánchez, Nahum and Eslam, Mohammed},
title = {MAFLD predicts cardiovascular disease risk better than MASLD},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15931}
}
EUVIMED